Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 174

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Feasibility of Identifying Pancreatic Cancer Based on Serum Metabolomics

Bathe, Oliver F., Shaykhutdinov, Rustem, Kopciuk, Karen, Weljie, Aalim M., McKay, Andrew, Sutherland, Francis R., Dixon, Elijah, Dunse, Nicole, Sotiropoulos, Dina, Vogel, Hans J.·2011·Cancer Epidemiology, Biomarkers & Prevention

Abstract

Background: We postulated that the abundance of various metabolites in blood would facilitate the diagnosis of pancreatic and biliary lesions, which could potentially prevent unnecessary surgery. Methods: Serum samples from patients with benign hepatobiliary disease (n = 43) and from patients with pancreatic cancer (n = 56) were examined by 1H NMR spectroscopy to quantify 58 unique metabolites. Data were analyzed by “targeted profiling” followed by supervised pattern recognition and orthogonal partial least-squares discriminant analysis (O-PLS-DA) of the most significant metabolites, which enables comparison of the whole sample spectrum between groups. Results: The metabolomic profile of patients with pancreatic cancer was significantly different from that of patients with benign disease (AUROC, area under the ROC curve, = 0.8372). Overt diabetes mellitus (DM) was identified as a possible confounding factor in the pancreatic cancer group. Thus, diabetics were excluded from further analysis. In this more homogeneous pancreatic cancer group, compared with benign cases, serum concentrations of glutamate and glucose were most elevated on multivariate analysis. In benign cases, creatine and glutamine were most abundant. To examine the usefulness of this test, a comparison was made to age- and gender-matched controls with benign lesions that mimic cancer, controlling also for presence of jaundice and diabetes (n = 14 per group). The metabolic profile in patients with pancreatic cancer remained distinguishable from patients with benign pancreatic lesions (AUROC = 0.8308). Conclusions: The serum metabolomic profile may be useful for distinguishing benign from malignant pancreatic lesions. Impact: Further studies will be required to study the effects of jaundice and diabetes. A more comprehensive metabolomic profile will be evaluated using mass spectrometry. Cancer Epidemiol Biomarkers Prev; 20(1); 140–7. ©2010 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1055-9965.epi-10-0712

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 174

Metadata

Authors
Bathe, O. F., Shaykhutdinov, R., Kopciuk, K., Weljie, A. M., McKay, A., Sutherland, F. R., Dixon, E., Dunse, N., Sotiropoulos, D., & Vogel, H. J.
Venue
Cancer Epidemiology, Biomarkers & Prevention
Published
2011-01-01
Volume
20
Issue
1
Pages
140-147
ISSN
  • 1055-9965 (ISSN-L)
  • 1538-7755
OpenAlex
W2154999108
Cited by
174
References
1
FWCI
6.82
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Feasibility of Identifying Pancreatic Cancer Based on Serum Metabolomics. https://app.cochat.ai/papers/10.1158/1055-9965.epi-10-0712
The paper
Bathe, O. F., Shaykhutdinov, R., Kopciuk, K., Weljie, A. M., McKay, A., Sutherland, F. R., Dixon, E., Dunse, N., Sotiropoulos, D., & Vogel, H. J. (2011). Feasibility of Identifying Pancreatic Cancer Based on Serum Metabolomics. Cancer Epidemiology, Biomarkers & Prevention. https://doi.org/10.1158/1055-9965.epi-10-0712

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.